Publications

Jacobsson S, Golparian D, Oxelbark J, Franceschi F, Brown D, Louie A, Drusano G and Unemo M

Pharmacodynamic evaluation of zoliflodacin treatment of Neisseria gonorrhoeae strains with amino acid substitutions in the zoliflodacin target GyrB using a dynamic hollow fiber infection model

Frontiers in Pharmacology (2022)

Jacobsson S, Kularatne R, Kittiyaowamarn R, Maseko V, Paopang P, Sangprasert P, Sirivongrangson P, Piddock L, Wi T, Alirol E, and Unemo M

High in vitro susceptibility to the first-in-class spiropyrimidinetrione zoliflodacin among consecutive clinical Neisseria gonorrhoeae isolates from Thailand (2018) and South America (2015-2017)

Antimicrobial Agents and Chemotherapy (2019)

Unemo M, Ahlstrand J, Sanchez-Buso, Day M, Aanensen D, Golparian D, Jacobsson S, Cole MJ and European Collaborative Group

High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018

Journal of Antimicrobial Chemotherapy (2021)

Newman LM, Kankam M, Nakamura A, Conrad T, Mueller J, O'Donnell J, Osborn BL, Gu K, Saviolakis GA

Thorough QT study to evaluate the effect of zoliflodacin, a novel therapeutic for gonorrhea, on cardiac repolarization in healthy adults

Antimicrobial Agents and Chemotherapy (2021)

Jacobsson S, Golparian D, Oxelbark J, Alirol FF, Gustafsson TN, Brown D, Louie A, Drusano G and Unemo M

Pharmacodynamic evaluation of dosing, bacterial kill, and resistance suppression for zoliflodacin against Neisseria gonorrhoeae in a dynamic hollow fiber infection model

Frontiers in Pharmacology (2021)

Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP and Rice PA

Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018)

Antimicrobial Agents and Chemotherapy (2021)

Theuretzbacher U, Barbee L, Connolly K, Drusano G, Fernandes P, Hook E, Jerse A, O'Donnell J, Unemo M, Van Bambeke F, VanScoy B, Warn P, Werth BJ, Franceschi F, and Alirol E

Pharmacokinetic/pharmacodynamic considerations for new and current therapeutic drugs for uncomplicated gonorrhoea – challenges and opportunities

Clinical Microbiology and Infection (2020)

Bradford PA, Miller AA, O’Donnell J, and Mueller JP

Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates

ACS Infectious Diseases (2020)

Miller AA, Traczewski MM, Huband MD, Bradford PA, Mueller JP

Determination of MIC quality control ranges for the novel gyrase inhibitor, zoliflodacin

Journal of Clinical Microbiology (2019)

Taylor SN, Marrazzo J, Batteiger BE, Hook EW, Seña AC, Long J, Wierzbicki MR, Kwak H, Johnson SM, Lawrence K, and Mueller J

Single-dose zoliflodacin (ETX0914) for treatment of urogenital gonorrhea

New England Journal of Medicine (2018)